Press Release Archive
-
Statement on Reuters Talc Article
-
Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
-
Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines
-
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
-
Cerenovus Launches Largest Global Registry to Study Stroke-Inducing Blood Clots Removed by Thrombectomy
-
Johnson & Johnson Works with U.S. PEPFAR Program to Expand Access for HIV Treatment-Experienced Children in the Developing World
-
New Phase 3 Study Findings Show IMBRUVICA® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia
-
New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
-
New Phase 3 CASSINI Data Presented on the Use of XARELTO® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients
-
Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma